Keel Point’s Axsome Therapeutics AXSM Stock Holding History

Keel Point’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,181	Closed	-$216K	–	476
2025 Q4	$216K	Buy	+1,181	New	+$165K	0.01%	490

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Keel Point's AXSM Position: Q1 2026 in Review

Keel Point sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,181 shares — an estimated $216K sold.

Keel Point first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $216K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Keel Point reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Keel Point sold 1,181 Axsome Therapeutics shares in Q1 2026, an estimated $216K.
Keel Point first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
Keel Point's Axsome Therapeutics position peaked at $216K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.